
Bortez2 gm/vial
Beacon Pharmaceuticals PLC
Bortezomib is a proteasome inhibitor chemotherapy agent used in the treatment of certain blood cancers.
Bortezomib is a proteasome inhibitor chemotherapy agent used in the treatment of certain blood cancers. Its evidence-based indications are:
For previously untreated multiple myeloma and previously untreated mantle cell lymphoma, Bortezomib must be used as part of a combination chemotherapy regimen rather than alone; see Dosage and Administration for regimen details.
Bortezomib is used only under the supervision of a physician experienced in the use of cancer chemotherapy.
Bortezomib 1.3 mg/m² in combination with oral melphalan and prednisone, given as a 9-cycle (approximately 54-week) regimen: twice weekly (Days 1, 4, 8, 11) with a 10-day rest during Cycles 1-4, then once weekly (Days 1, 8, 22, 29) during Cycles 5-9.
Bortezomib 1.3 mg/m² given twice weekly (Days 1, 4, 8, 11) followed by a 10-day rest period (Days 12-21), constituting one 21-day treatment cycle, alone or in combination regimens as directed by the treating oncologist.
Bortezomib 1.3 mg/m² twice weekly (Days 1, 4, 8, 11) followed by a 10-day rest, for up to 6 cycles, in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (VcR-CAP regimen).
Bortezomib 1.3 mg/m² twice weekly (Days 1, 4, 8, 11) followed by a 10-day rest period, as a single agent.
| Toxicity | Action |
|---|---|
| Grade 3 non-hematologic or Grade 4 hematologic toxicity | Withhold Bortezomib until toxicity resolves; resume at a 25% reduced dose |
| New or worsening peripheral neuropathy | Dose or schedule modification per established grading (see Precautions and Warnings) |
No initial dosage adjustment of Bortezomib is required for mild-to-severe renal impairment. In patients on hemodialysis, Bortezomib should be administered after the dialysis procedure.
Patients with mild hepatic impairment require no dose adjustment. Patients with moderate or severe hepatic impairment should be started at a reduced dose of approximately 0.7 mg/m² in the first cycle, with consideration for subsequent dose escalation to 1.0 mg/m² or further reduction to 0.5 mg/m² based on tolerability.
Bortezomib must be prepared and administered only by healthcare professionals experienced with cytotoxic chemotherapy, in a facility equipped to manage complications. See Administration and Reconstitution for route-of-administration details.
Adverse effects associated with Bortezomib range from very common to rare but serious:
Patients should promptly report new neurological symptoms, unusual bleeding or bruising, dizziness/fainting, shortness of breath, or signs of infection to their physician.
Bortezomib is contraindicated in:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.